William Rittmeyer, DO
Interventional Pain Medicine · Libertyville, ILNPI 1770088189
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 38.7% of the total. Reporting peaked in 2023 at $11,022 and has fallen 69.0% since, to $3,417 in 2025.
Across 262 payments — averaging $87.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Medtronic$5K
- Nevro Corp.$4K
- Boston Scientific$3K
- Saluda Medical Americas, Inc.$870
- Stratus Medical, LLC$333
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$1,3196%
- Grants$530%
- Travel & lodging$9,39441%
- Food & beverage$12,15853%
- Education$700%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 106 | $8,903 |
| Medtronic | 61 | $5,015 |
| Nevro Corp. | 35 | $3,982 |
| Boston Scientific | 25 | $2,665 |
| Saluda Medical Americas, Inc. | 4 | $870 |
| Stratus Medical, LLC | 6 | $333 |
| SPR Therapeutics, Inc | 7 | $268 |
| Nalu Medical, Inc. | 2 | $267 |
| Globus Medical | 5 | $245 |
| Merz Pharmaceuticals, LLC | 1 | $125 |
| Relievant Medsystems, Inc. | 1 | $114 |
| Stryker | 1 | $58 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Merck | 1 | $25 |
| Avanos Medical | 1 | $24 |
| Vertex | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Foundation Fusion Solutions, LLC | 1 | $16 |
| Vapotherm Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$6,434
- INTELLIS ADAPTIVESTIM$2,099
- Senza$1,567
- Omnia$1,455
- SYNCHROMEDII$1,268
- Evoke SCS$870
- Superion Indirect Decompression System$772
- GENERAL - THERAPIES$710
- WaveWriter Alpha Prime 16$616
- ETERNA$568
- Intracept$458
- Nalu Neurostimulation System$267
- Nimbus$185
- SPRINT PNS System$140
- OSTEOCOOL RF ABLATION SYSTEM$137
- GENERAL PAIN MANAGEMENT$132
- XEOMIN$125
How this compares
$22,992 in reported general payments places this provider in the 85th percentile of 93 interventional pain medicine providers in Illinois.
See all interventional pain medicine providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 74 | $74,313 |
| BelbucaBuprenorphine Hcl | 61 | $48,580 |
| Buprenorphine | 104 | $32,349 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 713 | $16,987 |
| OxycontinOxycodone Hcl | 19 | $12,145 |
| Hysingla ErHydrocodone Bitartrate | 12 | $9,496 |
| Celecoxib | 316 | $7,853 |
| Morphine Sulfate ErMorphine Sulfate | 255 | $7,669 |
| Pregabalin | 263 | $6,503 |
| Gabapentin | 441 | $5,613 |
| Lidocaine | 28 | $4,457 |
| Tramadol Hcl ErTramadol Hcl | 51 | $3,770 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 104 | $2,660 |
| Tramadol Hcl | 372 | $2,647 |
| Cyclobenzaprine Hcl | 176 | $2,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $34 | $122,893135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 interventional pain medicine providers in Illinois.
Other interventional pain medicine in Libertyville
- Michael McGinnisLibertyville$5K
- Alexander FeoktistovNorthfield$922K
- Timothy LubenowChicago$556K
- Sandeep AminChicago$430K
- Matthew JaycoxChicago$123K
- Hong VoChicago$91K
- Asokumar BuvanendranChicago$52K
- Ramsin BenyaminBloomington$32K
- Adam YoungChicago$29K
- Salman SagarwalaChicago$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.